Elevation Oncology CEO Shows Confidence: Retains 145K Shares After RSU Vesting

Rhea-AI Filing Summary

Joseph J. Ferra Jr., Chief Executive Officer and Director of Elevation Oncology (ELEV), reported two significant transactions on June 16, 2025:

• Acquired 12,560 shares of common stock through the vesting of Restricted Stock Units (RSUs)
• Subsequently disposed of 4,627 shares at $0.3854 per share, likely for tax withholding purposes

Following these transactions, Ferra's direct ownership stands at 145,085 shares. The RSUs, which originally vested 25% on June 16, 2022, followed by quarterly vesting of 1/16 of the total RSUs, have now been fully exercised. This insider activity provides insight into the executive compensation structure and demonstrates continued alignment between management and shareholder interests.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ferra Joseph J Jr

(Last) (First) (Middle)

C/O ELEVATION ONCOLOGY, INC.

101 FEDERAL STREET, SUITE 1900

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Elevation Oncology, Inc. [ ELEV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/16/2025		M		12,560	A	(1)	149,712	D
Common Stock	06/16/2025		F		4,627	D	$0.3854	145,085	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	06/16/2025		M			12,560	(2)	(3)	Common Stock	12,560	$0	0	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

2. 25% of the RSUs vested on June 16, 2022, and the remainder vested as to 1/16 of the total RSUs quarterly.

3. The RSUs do not expire; they either vest or are canceled prior to the vesting date.

	/s/ Robert Yang, Attorney-in-Fact	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider trading activity occurred at ELEV on June 16, 2025?

CEO Joseph J. Ferra Jr. acquired 12,560 shares through the vesting of Restricted Stock Units (RSUs) and subsequently disposed of 4,627 shares at a price of $0.3854 per share, leaving him with a total of 145,085 shares held directly.

How many ELEV shares does CEO Joseph Ferra own after the June 2025 transactions?

Following the reported transactions, CEO Joseph Ferra owns 145,085 shares of ELEV stock directly (Form D ownership). This amount reflects the acquisition of 12,560 shares from RSU vesting and the disposition of 4,627 shares.

What is the vesting schedule for ELEV CEO's Restricted Stock Units?

According to the filing, 25% of the RSUs vested on June 16, 2022, with the remaining RSUs vesting quarterly at a rate of 1/16 of the total RSU amount. The RSUs do not have an expiration date - they either vest or are canceled prior to the vesting date.

What positions does Joseph Ferra hold at ELEV as of June 2025?

Joseph Ferra serves as both the Chief Executive Officer and a Director of Elevation Oncology, Inc. (ELEV), as indicated by the checked boxes in Section 5 of the Form 4 filing.